The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 14, 2018

Filed:

Dec. 21, 2012
Applicant:

Monarch Medical Technologies, Llc, Charlotte, NC (US);

Inventors:

Timothy L. Ruchti, Gurnee, IL (US);

William Patrick Burgess, Charlotte, NC (US);

John Dumas, III, Libertyville, IL (US);

Ronald Lisiecki, Libertyville, IL (US);

Carol Dian Martin, Charlotte, NC (US);

Laura Santana, Charlotte, NC (US);

John Harrison Thornley, Charlotte, NC (US);

Joanne Marie Watt, Tower Lakes, IL (US);

Assignee:

Monarch Medical Technologies, LLC, Charlotte, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61M 31/00 (2006.01); A61M 5/172 (2006.01);
U.S. Cl.
CPC ...
A61M 5/1723 (2013.01);
Abstract

In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.


Find Patent Forward Citations

Loading…